The development of immunotherapy in older adults: New treatments, new toxicities?

Keyphrases

• Older Adults 100%
• Immune Checkpoint Blockers 100%
• Older Patients 75%
• Malignancy 25%
• Efficacy Data 25%
• Cancer Cells 25%
• Clinical Response 25%
• Immune Response 25%
• Monotherapy 25%
• Metastatic Melanoma 25%
• Non-small Cell Lung Cancer Cells 25%
• Molecular Targeted Therapy 25%
• Programmed Death-ligand 1 (PD-L1) 25%
• Life-threatening 25%
• Specific Populations 25%
• Renal Cancer 25%
• Multiple Cancers 25%
• Anticancer Therapeutics 25%
• Cancer Subtypes 25%
• Immune Checkpoint Molecules 25%
• Severe Immune-related Adverse Events 25%
• Immune-related Adverse Events (IrAEs) 25%
• Programmed Cell Death Protein 1 (PD-1) 25%
• Monoclonal Antibody Targeting 25%
• Unique Challenge 25%
• Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) 25%
• Specific Spectra 25%
• Immunotherapy Toxicity 25%

Medicine and Dentistry

• Immunotherapy 100%
• Cancer Cell 100%
• Immune-Related Adverse Events 100%
• Cancer 50%
• Proteus Syndrome 50%
• Monoclonal Antibody 50%
• Immune Response 50%
• Non Small Cell Lung Cancer 50%
• Monotherapy 50%
• Molecularly Targeted Therapy 50%
• Metastatic Melanoma 50%
• CTLA-4 50%
• Programmed Death-Ligand 1 50%
• Side Effect 50%

Immunology and Microbiology

• Cancer Cell 100%
• Immunotherapy 100%
• Monoclonal Antibody 50%
• CTLA-4 50%
• Immune Response 50%
• Programmed Death-Ligand 1 50%
• Lung 50%